

Rec. Nat. Prod. X:X (202X) XX-XX

records of natural products

Monoester-Type C₁₉-Diterpenoid Alkaloids from *Aconitum carmichaelii* and Their Cardiotoxicity

Qiao Lin ^{[1,2,3#}, Chunwang Meng ^{[1,2,3#}, Jie Liu ^[1,2,3], Qinmei Zhou ^[1,2,3],

Xingjie Ding ⁽¹⁾², Lulin Miao ⁽¹⁾², Xiaoya Wang ⁽¹⁾², Ou Dai ⁽¹⁾^{1,2,3*}

and Cheng Peng ^[0]

¹State Key Laboratory of Southwestern Chinese Medicine Resources, Chengdu University of Traditional Chinese Medicine, Chengdu 611137, P. R. China

²School of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu 611137, P. R.

China

³Innovative Medicine Ingredients of Southwest Specialty Medicinal Materials, Chengdu University of Traditional Chinese Medicine, Chengdu 611137, P. R. China

(Received July 08, 2021; Revised September 20, 2021; Accepted September 21, 2021)

Abstract: A new (1) and six known (2-7) monoester-type C_{19} -diterpenoid alkaloids were isolated from the lateral roots of *Aconitum carmichaelii* Debx. Their structures were determined by spectroscopic techniques and calculations of NMR chemical shifts. Compound 1 (1-*epi*-hokbusine A) was an aconitine-type diterpenoid alkaloid possessing an unusual 1 β -methoxy group. According to the main toxicity of the lateral roots of *A. carmichaelii*, the cardiotoxic effects of the isolates were evaluated using H9c2 rat myocardial cells and zebrafish embryos. The results showed that all the monoester-type C₁₉-diterpenoid alkaloids exhibited cardiotoxicity, and compound **6** was found to be the most toxic compound.

Keywords: *Aconitum carmichaelii*; monoester-type C₁₉-diterpenoid alkaloids; H9c2 cells; zebrafish embryos; cardiotoxicity. © 2021 ACG Publications. All rights reserved.

1. Introduction

The lateral roots of *Aconitum carmichaelii* Debx. (Ranunculaceae), named Fuzi in Chinese, were first documented in *Shennong's Materia Medica* (*Shennong Bencao Jing* in Chinese) approximately 2000 years ago and have been widely used in China [1-2]. In modern clinical applications, Fuzi is extensively used to treat heart failure, but it has great cardiotoxicity, including tachycardia, atrioventricular block, cardiogenic shock, and cardiac arrest [3-6]. Thus, the remarkable cardiotoxicity of Fuzi has attracted more and more attentions. C₁₉-diterpenoid alkaloids are confirmed as the main effective and toxic constituents of Fuzi and can be divided into three categories (diester-type, monoester-type, and aminoalcohol-type) based on the number of ester bonds. Diester-type C₁₉-diterpenoid alkaloids have a stronger cardiotoxicity than monoester-type C₁₉-diterpenoid alkaloids,

The article was published by ACG Publications

http://www.acgpubs.org/journal/records-of-natural-products Month-Month 202x EISSN:1307-6167 DOI: http://doi.org/10.25135/rnp.287.2107.2127

Available online: October 25, 2021

^{*} Corresponding author: E-Mail: <u>oudai1123@hotmail.com</u> (O. Dai); <u>pengcheng@cdutcm.edu.cn</u> (C. Peng).

Monoester-type C₁₉-diterpenoid alkaloids

followed by aminoalcohol-type C₁₉-diterpenoid alkaloids [4,7]. As for the aminoalcohol-type C₁₉diterpenoid alkaloids, researchers have mainly focused on their cardiotonic or cardioprotective effects [8,9]. In our previous studies, 14 aminoalcohol-diterpenoid alkaloids with cardioprotective effects were isolated from Fuzi, and their concentration-response and rudimentary structure-activity relationships were also investigated [10]. On the contrary, the diester-type C₁₉-diterpenoid alkaloids are believed to be the principal cardiotoxic substances of Fuzi. Especially, some representative alkaloids, such as aconitine, mesaconitine, and hypaconitine, have been intensively researched [11– 13]. However, few studies have looked at the cardiotoxicity of the monoester-type C₁₉-diterpenoid alkaloids [14]. Thus, this study performed a phytochemical investigation on the monoester-type C₁₉-diterpenoid alkaloids (1-7) (Figure 1) with cardiotoxicity were isolated, including an aconitine-type alkaloid possessing an unusual 1 β -methoxy group (1).



Figure 1. Structures of compounds 1-7

2. Materials and Methods

2.1. General experimental procedures

Anton Paar MCP 200 automatic polarimeter (Anton Paar GmbH, Austria) was used to detect the optical rotations. IR spectra were measured on an Agilent cary 600 FT-IR microscope instrument (Agilent Technologies Inc., CA, USA). Agilent 1260-MTQ-2 instrument (Agilent Technologies Inc., CA, USA) was applied to record HRESIMS spectra. NMR spectra were taken by a Bruker-Avance-Neo-600 spectrometer (Bruker Corporation, Billerica, MA, USA) using solvent peaks as references. TLC was conducted by silica gel GF254 plates (Qingdao Marine Chemical Inc., Qingdao, China). Column chromatography was performed using macroporous adsorbent resin (D-101; Anhui Sanxing Resin Technology Co., Ltd., Anhui, China), silica gel (Yantai Institute of Chemical Technology, Yantai, China), and Sephadex LH-20 (Amersham Pharmacia Biotech AB, Uppsala, Sweden). HPLC separations were performed using an Agilent 1100 instrument (Agilent Technologies Inc., CA, USA) equipped with an Ultimate XB-C18 (250 \times 10 mm, 5 μ m). Fetal bovine serum (FBS) was from Cao Yuan Lv Ye Bio-engineering Materials Co., Ltd. (Hohhot, China). 3-(4,5-Dimethylthiazol-2-yl)-2,5diphenyl tetrazolium (MTT) was purchased from Sigma-Aldrich Corporation (St. Louis, Missouri, US). Varioskan advanced multifunctional enzyme marker (Thermo, USA) measured the OD values. Leica M165Fic fluorescence microscope (Leica Microsystems, Germany) was used to observe the morphological changes of zebrafish.

2.2. Plant Material

A. carmichaelii were obtained from Sichuan Jiangyou Zhongba Fuzi Technology Development Co., Ltd. (Jiangyou, Sichuan, China and its voucher specimen (SFZ-0710) was deposited in the Institute of Innovative Medicine Ingredients of Southwest Specialty Medicinal Materials, Chengdu University of TCM, Sichuan, China [10].

2.3. Extraction and Isolation

For extraction and preliminary fractionation of Fuzi, refer to reference [10]. Separation of portion E (12 g) was performed via RP-MPLC eluted by a gradient solvent system (10-100% MeOH in H_2O) to get 14 fractions (E_1 - E_{14}). Fraction E_1 was purified by preparative TLC (CH₂Cl₂/MeOH/NH₃·H₂O, 15:1:0.1) and HPLC (MeOH/H₂O, 38:62) to afford compound **6** (3.1 mg). E_{2-1} - E_{2-6} were afforded by chromatographing E₂ over Sephadex LH-20 column chromatography (petroleum ether/CH₂Cl₂/MeOH, 2:2:1). Successive purification of subfraction E₂₋₆ by TLC (CH₂Cl₂/MeOH/NH₃·H₂O, 10:1:0.1) and RP HPLC (35% MeOH in H₂O, containing 0.1% acetic acid) yielded compound 5 (2.5 mg). Fraction E₃ was separated by silica gel column chromatography (petroleum ether/Me₂CO/diethylamine, 10:1:0.1 to 3:1:0.1), followed by preparative TLC (CH₂Cl₂/MeOH/NH₃·H₂O, 10:1:0.1) to yield compound 2 (4.2 mg). Fraction E₄ was further divided into E₄₋₁-E₄₋₃ by silica gel column chromatography (petroleum ether/Me₂CO/diethylamine, 10:1:0.1 to 3:1:0.1). Purification of subfraction E_{4-2} by RP semipreparative HPLC (44% MeCN in H₂O, containing 0.1% TFA) afforded compound 1 (4.2 mg). Subfraction E₄₋₃ was purified by preparative TLC (petroleum ether/Me₂CO/diethylamine, 3:1:0.1) to yield compound 3 (3.6 mg). Fraction E_7 was chromatographed via a Sephadex LH-20 column (CH₂Cl₂/MeOH, 1:1) to obtain E₇₋₁-E₇₋₄. Subfraction E₇₋₃ was further purified by RP-HPLC (20% MeCN in H_2O) to furnish compounds 4 (6.3 mg) and 7 (4.5 mg).

2.4. Spectral Data

1-epi-Hokbusine A (1): white powder; $[\alpha]_{D}^{20}$ –11.7 (*c* 0.05, MeOH); ¹H (acetone-*d*₆, 600 MHz) and ¹³C NMR (acetone-*d*₆, 150 MHz) data, see Tables 1 and 2. IR (ATR) *v*_{max} 3365, 2923, 1676, 1278, 1099, 718 cm⁻¹; (+)-HR-ESI-MS *m*/*z* 604.3121 [M + H]⁺ (calcd. for C₃₂H₄₆NO₁₀, 604.3122).

2.5. Cell culture

H9c2 cells were cultured in accordance with literature methods [10].

2.6. Determination of H9c2 Cell Viability

The H9c2 cell viability was assessed by the activity of mitochondrial dehydrogenases using a colorimetric MTT method. Exponentially growing cells were plated into 96-well plates (7×10^3 cells per well) and incubated for 24 h. Then the cells were treated with the isolated compounds at concentrations of 1.56, 3.125, 6.25, 12.5, 25, and 50 μ M for 24 h. Then, 0.5 mg/mL MTT was added into each well. After a 4-hour incubation at 37°C, the purple formazan crystals were dissolved in 0.18 mL of DMSO. The optical density ratios were measured on an automated MK3 microplate spectrophotometer (Thermo Fisher Scientific, Waltham, MA, US) at 490 nm.

2.7. Zebrafish Husbandry

Zebrafish of wild-type AB strain obtained from China Zebrafish Resource Center were maintained and raised according to the routine procedures [15]. All zebrafish were kept at 28.5° C under a 14-h light/10-h dark cycle. The embryos were generated by natural spawning and maintained in the embryonic medium (15 μ M NaCl, 500 μ M KCl, 1 mM CaCl₂, 500 μ M NaHCO₃, 74 μ M Na₂HPO₄, 1 mM MgSO₄, and 120 μ M KH₂PO₄ in distilled H₂O). The zebrafish experiments were performed under the approval of the Institutional Animal Care and Use Committee of Chengdu University of Traditional Chinese Medicine.

Monoester-type C19-diterpenoid alkaloids

2.8. Assessment of Zebrafish Malformation Rates and Heart Rates

Zebrafish embryos were distributed into 24-well microplates after 48 h post fertilization (hpf), and at least 15 fish were placed in each well. One well of embryos were treated with 0.1% (v/v) DMSO embryo medium (the control group), and other wells were treated with various concentrations of the isolated alkaloids (6.25, 12.5, 25, and 50 μ M). Plates were cultivated at 28.5°C for 24 h. The acute toxicity of zebrafish exposed to the isolated alkaloids was determined by observing the changes in zebrafish morphology and examining the malformation rates under a Leica M165Fic fluorescence microscope (Leica Microsystems). At the same time, 60-second video images were collected for mensurable assessment of the heart rates.

2.9. Data Analysis

Data analyses were prepared using SPSS 19.0 software (IBM Corp.). Data are shown as the mean \pm standard deviation (SD). Statistical significance was assessed by one-way analysis of variance (ANOVA), followed by a least-significant-difference (LSD) test. Figures were manufactured using GraphPad Prism software Version 5.0 (GraphPad Software, Inc.). In all comparisons, P < 0.05 indicated a statistically significant difference.

3. Results and Discussion

3.1. Structure Elucidation

Compound 1 was separated as a white powder possessing a molecular formula of $C_{32}H_{45}NO_{10}$, based on a quasi-molecular ion at m/z 604.3121 [M + H]⁺ (calcd. for C₃₂H₄₆NO₁₀, 604.3122) in its HRESIMS. The IR spectrum of 1 showed characteristic absorptions for the carbonyl (1676 cm⁻¹) and OH (3365 cm⁻¹) functionalities. The ¹H NMR spectrum of compound **1** (Table 1) showed signals attributed to five methoxy groups ($\delta_{\rm H}$ 3.18, 3.32, 3.37, 3.41, and 3.70), six oxymethine groups [$\delta_{\rm H}$ 3.42 (1H, d, J = 6.0 Hz, H-16), 3.71 (1H, brs, H-1), 4.26 (1H, dd, J = 6.6, 1.8 Hz, H-6), 4.29 (1H, brd, J = 4.2 Hz, H-3), 4.70 (1H, d, J = 6.0 Hz, H-15), and 4.87 (1H, d, J = 5.4 Hz, H-14)], an isolated oxymethylene group [$\delta_{\rm H}$ 3.43 (1H, overlapped, H-18a) and 3.59 (1H, d, J = 7.8 Hz, H-18b)], a Nmethyl group [$\delta_{\rm H}$ 3.15 (3H, s, H₃-20)], an isolated *N*-methylene group [$\delta_{\rm H}$ 3.45 (1H, d, J = 12.0 Hz, H-19a) and 3.65 (1H, d, J = 12.0 Hz, H-19b)], a characteristic *N*-methine group [$\delta_{\rm H}$ 3.47 (1H, s, H-17)], and a monosubstituted aromatic ring [$\delta_{\rm H}$ 7.53 (2H, t, J = 7.8 Hz, H-3' and H-5'), 7.65 (1H, m), and 8.06 (2H, dd, J = 7.8, 1.2 Hz, H-2' and H-6')]. The ¹³C NMR (Table 2) and DEPT data exhibited 32 carbons signals, including six methyls (five oxygenated, $\delta_{\rm C}$ 50.3, 55.5, 59.1, 59.3, and 62.5), four methylenes (one oxygenated, $\delta_{\rm C}$ 77.4), 16 methines (six oxygenated, $\delta_{\rm C}$ 70.2, 76.8, 80.0, 80.8, 82.8, and 94.5), and six quaternary carbons (two oxygenated, δ_C 75.4 and 83.5; one aromatic, δ_C 131.1; and one carbonylic, $\delta_{\rm C}$ 166.3). These spectroscopic data revealed that compound 1 was a typical benzoylaconitine-type diterpenoid alkaloid with five methoxy and three hydroxy groups. The planar structure of compound 1 was further confirmed to be the same as hokbusine A [16] by the ${}^{1}H{}^{-1}H$ COSY and HMBC correlations (Figure 2). However, in comparison with the ¹³C NMR data of hokbusine A, C-1, C-2, and C-3 in 1 were shielded by $\Delta \delta_{\rm C}$ -1.9, -3.7, and -1.5 ppm, respectively, whereas C-17 and C-19 were deshielded by $\Delta \delta_{\rm C}$ +5.3 and +2.1 ppm. These differences suggested that compound 1 and hokbusine A might be C-1 epimers [16]. In the ROESY spectrum of 1, the correlations of H-10 with H-6 and H-14, of H-6 with H-9 and OMe-16, of H-15 with OMe-8 and H-18a, of H-3 with H-18a, of H-12b with H-14; and of H-12a with H-1, H-16, and H-17, demonstrated that OH-3, OH-15, and OMe-6 were α -oriented, while OMe-1, H-14, and OMe-16 groups were in the β -orientation. Meanwhile, in the 1D-NOE experiment of **1**, irradiation of H-7 enhanced H-15, and irradiation of H-6 enhanced H-9, while irradiation of H-12a enhanced H-1, H-16, and H-17.

These enhancements supported the above configurations. In addition, calculations of NMR chemical shifts were used to further confirm the configuration of C-1. Conformational analyses of **1a** and **1b** (Figure 3) were accomplished via Monte Carlo searching with the MMFF94s molecular mechanics force field by the MOE 2008 software. The conformers were optimized using DFT at the B3LYP/6-31G (d) level in vacuum with the Gaussian 16 program. The NMR data of **1a** with 1 β -OMe and **1b** with 1 α -OMe (Figure 3) were calculated at the PCM/mPW1PW91/6-311 + G (d,p) level by the GIAO method [17]. The calculated ¹³C NMR chemical shifts of **1a** presented a better agreement with the experimental values of **1** with a higher correlation coefficient (R², **1a**: 0.9965; **1b**: 0.9884, Figure 4). Furthermore, DP4+ probability analysis [18] based on both ¹H and ¹³C NMR data deduced **1a** as the correct configuration with 100% probability (Supplementary data, Tables S7 and S8). Therefore, the ROESY data, 1D-NOE data, and NMR calculations verified that the OMe group at C-1 in compound **1** was β -oriented. Compound **1** was determined to be 1-*epi*-hokbusine A.



Figure 2. Key ¹H⁻¹H COSY, HMBC, and ROESY correlations of 1.



Figure 3. Proposed configurations of C-1 in 1a and 1b

Monoester-type C19-diterpenoid alkaloids



Figure 4. Correlation plots of experimental ¹³C NMR chemical shifts versus corresponding calculated ¹³C NMR chemical shifts for **1a** (**A**) and **1b** (**B**).

By comparing the experimental and literature NMR data, six known compounds were identified as 14-benzoylmesaconine (2) [19], 14-benzoylaconine (3) [20], 14-benzoylneoline (4) [21], carmichaenine C (5) [22], (-)-(A-b)-14a-benzoyloxy-*N*-ethyl-1 α ,8 β ,15 α -trihydroxy-6 α ,16 β ,18-trimethoxyaconitane (6) [23], and 14-*O*-cinnamoylneoline (7) [24].

No.	hokbusine A	1	No.	hokbusine A	1
1	3.22 brt (6.4)	3.71 brs	16	3.25 m	3.42 d (6.0)
2a	2.02 m	1.64 dt (16.2, 4.2)	17	2.87 brs	3.47 s
2b	2.34 m	2.38 d (16.2)	18a	3.55 d (8.7)	3.43 (overlapped)
3	3.75 dd (8.2, 5)	4.29 brd (4.2)	18b	3.61 d (8.7)	3.59 d (7.8)
4	-	-	19a	2.50 m	3.45 d (12.0)
5	2.10 m	2.60 d (6.6)	19b	2.73 m	3.65 d (12.0)
6	4.03 d (7.0)	4.26 dd (6.6, 1.8)	20	2.38 s	3.15 s
7	2.85 brs	3.12 d (1.8)	1′	-	-
8	-	-	2'/6'	8.01 d (7.4)	8.06 dd (7.8, 1.2)
9	2.58 t (6.0)	2.63 dd (7.2, 5.4)	3'/5'	7.43 t (7.4)	7.53 t (7.8)
10	2.07 m	2.56 m	4'	7.54 t (7.5)	7.65 m
11	-	-	7'	-	-
12a	2.07 m	1.93 m	OCH ₃ -1	3.28 s	3.41 s
12b	2.70 m	2.33 m	OCH ₃ -6	3.28 s	3.37 s
13	-	-	OCH ₃ -8	3.12 s	3.18 s
14	4.82 d (5.1)	4.87 d (5.4)	OCH ₃ -16	3.71 s	3.70 s
15	4.52 d (6.0)	4.70 d (6.0)	OCH ₃ -18	3.30 s	3.32 s

Table 1. ¹H NMR data for compound **1** (600 MHz) and hokbusine A [16]

No.	hokbusine A	1	No.	hokbusine A	1
1	82.7	80.8	16	93.4	94.5
2	34.0	30.3	17	62.6	67.9
3	71.7	70.2	18	76.7	77.4
4	43.7	44.2	19	50.1	52.2
5	45.8	42.5	20	42.8	42.0
6	83.3	82.8	1'	56.5	131.1
7	41.6	43.4	2'/6'	130.0	130.4
8	82.5	83.5	3'/5'	128.7	129.3
9	45.4	45.0	4′	133.3	133,9
10	41.9	40.9	7'	166.4	166.3
11	50.7	51.7	OCH ₃ -1	56.5	55.5
12	36.4	36.6	OCH ₃ -6	58.8	59.1
13	75.1	75.4	OCH ₃ -8	50.0	50.3
14	79.7	80.0	OCH3-16	62.9	62.5
15	77.8	76.8	OCH ₃ -18	59.4	59.3

Table 2. ¹³C NMR data for compound 1 (150 MHz) and hokbusine A [16]

3.2. Cardiotoxicity On H9c2 Cells

The cardiotoxicity of seven isolated monoester-type C₁₉-diterpenoid alkaloids (1-7) were evaluated using H9c2 cells and zebrafish embryos. As shown in Figure 5, all the alkaloids exhibited significant toxicity in H9c2 cells at concentrations of 1.56, 3.125, 6.25, 12.5, 25, and 50 μ M. Among them, compounds 2 and 6 showed the strongest toxicity in a dose-dependent manner. Particularly, the survival rates of compounds 2 and 6 at 50 μ M decreased to 46.73 \pm 3.81% and 48.80 \pm 4.54%, respectively. Comparison of compounds 2 and 3 suggested that the monoester-type C₁₉-diterpenoid alkaloids with a N-CH₃ group had stronger cytotoxicity than those with a N-CH₂CH₃ group. When compared with compound 4, introduction of an α -OH group at C-15 in compound 6 improved the cytotoxicity. In addition, replacement of a benzoyl group (4) by a cinnamyl group (7) resulted in loss of the cytotoxicity. Therefore, it can be inferred that the alkyl group at N, the acyloxy group at C-14, and the hydroxy group at C-15 have significant effects on the cytotoxicity of monoester-type C₁₉diterpenoid alkaloids in H9c2 cells. Monoester-type C₁₉-diterpenoid alkaloids



Figure 5. Cytotoxic effects of compounds 1-7 in H9c2 cells. Results are showed as the mean \pm SD for three individual experiments. **P* < 0.05, ***P* < 0.01 vs the control group.

3.3. Cardiotoxicity On Zebrafish Embryos

After treatment with the isolated monoester-type C₁₉-diterpenoid alkaloids at 6.25, 12.5, 25, and 50 μ M, the zebrafish embryos developed abnormally with symptoms of cardiotoxicity. As shown in Figure 6, the representative toxic compounds (**2** and **6**) had notable cardiotoxic effects on the heart morphology of zebrafish, mainly including the serious pericardial edema and yolk sac edema. Furthermore, Figure 7 showed that the malformation rates of zebrafish treated with the monoester-type C₁₉-diterpenoid alkaloids increased significantly, especially the malformation rates of zebrafish treated with compounds **2** and **6** at 25 and 50 μ M. In addition to the malformation rates, the heart rates of zebrafish were also affected by the above alkaloids (Figure 8). Particularly, the average heart rate of the control zebrafish embryos was 164.5 ± 3.42 beats/min, while the average heart rates increased to 179.5 ± 1.92 (compound **1**), 192.5 ± 7.72 (compound **2**), 173.5 ± 4.44 (compound **3**), 172.5 ± 3.42 (compound **5**), and 188 ± 8.64 beats/min (compound **6**) at 50 μ M. These results indicated that the isolated monoester-type C₁₉-diterpenoid alkaloids had cardiotoxic effects on H9c2 cells and zebrafish embryos.



Figure 6. Effects of compounds 2 and 6 on the heart morphology of zebrafish.



Figure 7. Effects of compounds 1-7 on malformation rates of zebrafish. Results are presented as the mean \pm SD for three individual experiments. *P < 0.05, **P < 0.01 vs the control group.



Figure 8. Effects of compounds 1-7 on heart rates of zebrafish. Results are presented as the mean \pm SD for three individual experiments. **P* < 0.05, ***P* < 0.01 vs the control group.

4. Conclusion

So far, more than 80 C₁₉-diterpenoid alkaloids have been isolated from Fuzi [4,14,25]. It is worth noting that the substituent group at C-1 is mostly α -oriented [4,26,27]. However, in this study, we obtained a monoester-type C₁₉-diterpenoid alkaloid possessing an unusual 1 β -methoxy group (1). In addition, researchers have increasingly focused on the cardiotoxicity of diester-type C₁₉-diterpenoid alkaloids in Fuzi, but few studies have looked at the cardiotoxicity of monoester-type C₁₉-diterpenoid alkaloids. This study demonstrated that all the isolated monoester-type C₁₉-diterpenoid alkaloids had cardiotoxic effects on H9c2 cells and zebrafish embryos. Thus, this study has greatly improved the understanding of the cardiotoxicity of Fuzi.

Monoester-type C19-diterpenoid alkaloids

Acknowledgments

This study was funded by the National Natural Science Foundation of China (NNSFC; Nos. 81630101, 81891012, and 81891010), the Sichuan Science and Technology Program (Grant No. 2018JZ0081), and the "Xinglin Scholar" Plan of Chengdu University of Traditional Chinese Medicine (Grant Nos. YXRC2018005, BSH2019028, and QNXZ2019030).

Supporting Information

Supporting information accompanies this paper on <u>http://www.acgpubs.org/journal/records-of-natural-products</u>

ORCID 回

Qiao Lin: 0000-0002-8828-7741 Chunwang Meng: 0000-0002-2119-7039 Jie Liu: 0000-0003-4174-2193 Qinmei Zhou: 0000-0002-5068-4725 Xingjie Ding: 0000-0002-8532-0649 Lulin Miao: 0000-0002-8562-9718 Xiaoya Wang: 0000-0002-9742-0313 Ou Dai: 0000-0001-6120-1138 Cheng Peng: 0000-0003-3303-906X

Author Contribution

[#]Q. Lin. and C. W. Meng contributed equally.

References

- [1] Q. W. Huang, Z. Y. Zhou, J. Wang and R. H. Liu (2011). Studies of traditional Chinese pharmaeutical processe for *Aconitum Carmichalii* Debx in medical history, *Chin. J. Exp. Tradit. Med. Form.* **17**, 269-271.
- [2] S. H. Dong, J. Meng, M. H. Wu, Z. G. Ma, H. Cao and Y. Zhang (2020). Herbalogical study of Aconiti lateralis Radix praeparata (Fuzi), Chin. J. Chin. Mater. Med. 45, 5567-5575.
- [3] J. L. Zhang, Z. J. Zeng, B. Zhang and S. Q. Yu (2014). Analysis clinical adverse reactions of *Aconiti lateralis* Radix *praeparata*, *Chin. J. Exp. Tradit. Med. Form.* **20**, 228-231.
- [4] G. Zhou, L. Tang, X. Zhou, T. Wang, Z. Kou and Z. Wang (2015). A review on phytochemistry and pharmacological activities of the processed lateral root of *Aconitum carmichaelii* Debeaux, *J. Ethnopharmacol.* **160**, 173-193.
- [5] D. D. Yang, Q. Zhang and F. C. Liu (2019). Effects of licorice concentrated decoction in treatment of arrhythmia caused by monkshood poisoning: A retrospective clinical study, *Chin. J. Tradit. Chin. Med. Pharm.* **34**, 417-419.
- [6] J. He, P. Wu, Y. Dong and R. Gao (2019). Adverse reactions analysis of Aconiti Lateralis Radix Praeparata and mechanism prediction of cardiac toxicity by network pharmacology, *Chin. J. Chin. Mater. Med.* 44, 1010-1018.
- [7] M. Yang, X. Ji and Z. Zuo (2018). Relationships between the toxicities of Radix *Aconiti lateralis preparata* (Fuzi) and the toxicokinetics of its main diester-diterpenoid alkaloids, *Toxins* **10**, 391.
- [8] Z. T. Zhang, X. X. Jian, J. Y. Ding, H. Y. Deng, R. B. Chao, Q. H. Chen, D. L. Chen and F. P. Wang (2015). Further studies on structure-cardiac activity relationships of diterpenoid alkaloids, *Nat. Prod. Commun.* 10, 2074-2085.
- [9] X. Chen, Y. Cao, H. Zhang, Z. Zhu, M. Liu, H. Liu, X. Ding, Z. Hong, W. Li, D. Lv, L. Wang, X. Zhuo, J. Zhang, X. Q. Xie and Y. Chai (2014). Comparative normal/failing rat myocardium cell membrane chromatographic analysis system for screening specific components that counteract doxorubicin-induced heart failure from *Acontium carmichaeli*, *Anal. Chem.* 86, 4748-4757.

- [10] X. Y. Wang, Q. M. Zhou, L. Guo, O. Dai, C. W. Meng, L. L. Miao, J. Liu, Q. Lin, C. Peng and L. Xiong (2021). Cardioprotective effects and concentration-response relationship of aminoalcohol-diterpenoid alkaloids from *Aconitum carmichaelii*, *Fitoterapia* 149, 104822.
- [11] F. Liu, X. Han, N. Li, K. Liu and W. Kang (2019). Aconitum alkaloids induce cardiotoxicity and apoptosis in embryonic zebrafish by influencing the expression of cardiovascular relative genes, *Toxicol. Lett.* **305**, 10-18.
- [12] C. Bi, T. Zhang, Y. Li, H. Zhao, P. Zhang, Y. Wang, Y. Xu, K. Gu, Y. Liu, J. Yu, W. Qi, S. Fan, Y. Li and Y. Zhang (2020). A proteomics- and metabolomics-based study revealed that disorder of palmitic acid metabolism by aconitine induces cardiac injury, *Chem. Res. Toxicol.* **33**, 3031-3040.
- [13] M. Li, X. Xie, H. Chen, Q. Xiong, R. Tong, C. Peng and F. Peng (2020). Aconitine induces cardiotoxicity through regulation of calcium signaling pathway in zebrafish embryos and in H9c2 cells, *J. Appl. Toxicol.* **40**, 780-793.
- [14] X. Zong, X. Yan, J. L. Wu, Z. Liu, H. Zhou, N. Li and L. Liu (2019). Potentially cardiotoxic diterpenoid alkaloids from the roots of *Aconitum carmichaelii*, *J. Nat. Prod.* **82**, 980-989.
- [15] M. Westerfield (2000). The Zebrafish Book. A guide for the laboratory use of zebrafish (Danio Rerio), 4th ed. University of Oregon Press, Eugene.
- [16] D. H. Wei, F. Wang, B. Song, J. C. Cui, X. M. Song and Z. G. Yue (2015). Diterpenoid alkaloids from Aconitum Penduli Radix and their bioactivities, *Chin. J. Exp. Tradit. Med. Form.* **21**, 48-52.
- [17] M. W. Lodewyk, M. R. Siebert and D. J. Tantillo (2012). Computational prediction of ¹H and ¹³C chemical shifts: A useful tool for natural product, mechanistic, and synthetic organic chemistry, *Chem. Rev.* **112**, 1839-1862.
- [18] N. Grimblat, M. M. Zanardi and A. M. Sarotti (2015). Beyond DP4: an improved probability for the stereochemical assignment of isomeric compounds using quantum chemical calculations of NMR shifts, *J. Org. Chem.* **80**, 12526-12534.
- [19] K. Ishimi, M. Makino, Y. Asada, Y. Ichinohe and Y. Fujimoto (2006). Norditerpenoid alkaloids from *Aconitum manshuricum, J. Nat. Med.* **60**, 255-257.
- [20] Z. Li, G. Lu, D. Chen and F. Wang (1997). Chemical study on the alkaloids of "Cao Wu", *Nat. Prod. Res. Dev.* **9**, 9-14.
- [21] K. Wada, H. Bando, T. Mori, R. Wada, Y. Kanaiwa and T. Amiya (1985). Studies on the constituents of Aconitum species. III.1) on the components of *Aconitum subcuneatum* NAKAI, *Chem. Pharm. Bull.* 33, 3661.
- [22] X. Qin, S. Yang, Y. Zhao, Y. Gao, F. Ren, D. Zhang and F. Wang (2015). Five new C₁₉-diterpenoid alkaloids from *Aconitum carmichaelii*, *Phytochem. Lett.* **13**, 390-393.
- [23] B. Jiang, S. Lin, C. Zhu, S. Wang, Y. Wang, M. Chen, J. Zhang, J. Hu, N. Chen, Y. Yang and J. Shi (2012). Diterpenoid alkaloids from the lateral root of *Aconitum carmichaelii*, J. Nat. Prod. 75, 1145-1159.
- [24] S. H. Shim, J. S. Kim and S. S. Kang (2003). Norditerpenoid alkaloids from the processed tubers of *Aconitum carmichaeli, Chem. Pharm. Bull.* **51**, 999-1002.
- [25] Y. Li, F. Gao, J. F. Zhang and X. L. Zhou (2018). Four new diterpenoid alkaloids from the roots of *Aconitum carmichaelii, Chem. Biodivers.* **15**, e1800147.
- [26] M. Tang, L. C. Zhao, M. Xu, J. Leng, N. Tang, Z. Y. Hu and Q. H. Zhang (2017). Chemical constituents and pharmacological activities of *Aconiti ateralis* Radix *praeparata, Guihaia* **37**, 1614-1627.
- [27] X. C. Zhang, Q. G. Zheng, J. H. Yang, R. Rong and Y. Yang (2020). Research progress on structure and activity of C₁₉ diterpenoid alkaloids from *Aconiti lateralis* Radix *praeparata*, *Chin. Tradit. Herbal Drugs* 51, 531-541.

